High-Density Lipoprotein Functionality in Coronary Artery Disease

被引:34
|
作者
Kosmas, Constantine E. [1 ]
Christodoulidis, Georgios [2 ]
Cheng, Jeh-wei [3 ]
Vittorio, Timothy J. [4 ]
Lerakis, Stamatios [3 ]
机构
[1] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[2] Winthrop Univ Hosp, Dept Internal Med, Mineola, NY 11501 USA
[3] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[4] St Francis Hosp Heart Ctr, Div Cardiol, Ctr Adv Cardiac Therapeut, Roslyn, NY USA
关键词
High-density lipoprotein functionality; High-density lipoprotein particles; Cardiovascular risk; Apolipoprotein A-1 Milano; Cholesteryl ester transfer protein inhibitors; Cholesterol efflux capacity; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; REVERSE CHOLESTEROL TRANSPORT; CARDIOVASCULAR-DISEASE; ANTIINFLAMMATORY PROPERTIES; HDL CHOLESTEROL; VASCULAR EVENTS; HIGH-RISK; ATHEROSCLEROSIS; METABOLISM;
D O I
10.1097/MAJ.0000000000000231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of high-density lipoprotein (HDL) in cardiovascular atheroprotection is well established. Epidemiological data have clearly demonstrated an inverse relationship between HDL levels and the risk for coronary artery disease, which is independent of the low-density lipoprotein levels. However, more recent data provide evidence that high HDL levels are not always protective and that under certain conditions may even confer an increased risk. Thus, a new concept has arisen, which stresses the importance of HDL functionality, rather than HDL concentration per se, in the assessment of cardiovascular risk. HDL functionality is genetically defined but can also be modified by several environmental and lifestyle factors, such as diet, smoking or certain pharmacologic interventions. Furthermore, HDL is consisted of a heterogeneous group of particles with major differences in their structural, biological and functional properties. Recently, the cholesterol efflux capacity from macrophages was proven to be an excellent metric of HDL functionality, because it was shown to have a strong inverse relationship with the risk of angiographically documented coronary artery disease, independent of the HDL and apolipoprotein A-1 levels, although it may not actually predict the prospective risk for cardiovascular events. Thus, improving the quality of HDL may represent a better therapeutic target than simply raising the HDL level, and assessment of HDL function may prove informative in refining our understanding of HDL-mediated atheroprotection.
引用
收藏
页码:504 / 508
页数:5
相关论文
共 50 条
  • [1] High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
    Favari, Elda
    Thomas, Michael J.
    Sorci-Thomas, Mary G.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 71 (06) : 325 - 331
  • [2] High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
    He, Yi
    Kothari, Vishal
    Bornfeldt, Karin E.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (02) : e10 - e16
  • [3] High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
    Silbernagel, Guenther
    Schoettker, Ben
    Appelbaum, Sebastian
    Scharnagl, Hubert
    Kleber, Marcus E.
    Grammer, Tanja B.
    Ritsch, Andreas
    Mons, Ute
    Holleczek, Bernd
    Goliasch, Georg
    Niessner, Alexander
    Boehm, Bernhard O.
    Schnabel, Renate B.
    Brenner, Hermann
    Blankenberg, Stefan
    Landmesser, Ulf
    Maerz, Winfried
    EUROPEAN HEART JOURNAL, 2013, 34 (46) : 3563 - 3571
  • [4] From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease
    Sacks, Frank M.
    Jensen, Majken K.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (03) : 487 - 499
  • [5] High-density lipoprotein lipid peroxidation as a diagnostics biomarker in coronary artery disease
    Yazdandoust, Shima
    Parizadeh, Seyyed Mohammad Reza
    Ghayour-Mobarhan, Majid
    Yaghmaei, Parichehreh
    Sahebkar, Amir Hossein
    BIOFACTORS, 2022, 48 (03) : 634 - 642
  • [6] Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
    Katz, Pamela M.
    Leiter, Lawrence A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (06) : 667 - 677
  • [7] High-density lipoprotein functionality in systemic lupus erythematosus
    Ganjali, Shiva
    Shirmohammadi, Leila
    Read, Morgayn, I
    Sahebkar, Amirhossein
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 769 - 775
  • [8] Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease
    Jose Badimon, Juan
    Ibanez, Borja
    REVISTA ESPANOLA DE CARDIOLOGIA, 2010, 63 (03): : 323 - 333
  • [9] High density lipoprotein as a therapeutic target: Focus on its functionality
    Rosso, Leonardo Gomez
    Davico, Belen
    Chiappe, Zequiel Lozano
    Tetzlaff, Walter
    Boero, Laura
    Brites, Fernando
    Martin, Maximiliano
    BIOCELL, 2023, 47 (11) : 2361 - 2383
  • [10] Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction
    Davidson, Michael H.
    CARDIOLOGY CLINICS, 2011, 29 (01) : 105 - +